FOR THE NEXT GENERATION OF PHYSICIANS
← All USMLE guides
HEMATOLOGY AND ONCOLOGY

Breast cancer: types, receptors, BRCA and screening.

Ductal and lobular carcinoma, estrogen and HER2 receptors, tamoxifen, trastuzumab, BRCA mutations and mammography screening.

Breast cancer questions focus on receptor status and treatment, hereditary risk and screening intervals.

Types

Invasive ductal carcinoma is most common. Invasive lobular carcinoma shows loss of E-cadherin and a targetoid pattern. Paget disease of the nipple shows eczema and underlying carcinoma. Inflammatory breast cancer involves dermal lymphatics (peau d'orange).

Treatment by receptor

ER or PR positive tumors respond to tamoxifen (endometrial hyperplasia risk) or aromatase inhibitors (osteoporosis risk). HER2 positive tumors respond to trastuzumab (cardiotoxicity). Triple negative tumors need chemotherapy.

Genetics and screening

BRCA1 and BRCA2 raise breast and ovarian cancer risk; BRCA2 raises male breast and prostate cancer risk. Average-risk screening mammography is offered starting between 40 and 50, every one to two years, depending on the guideline. A palpable mass in a young woman is evaluated with ultrasound.

Keep going in hematology and oncology

Related on USMLE WEB

Frequently asked questions

Which drug targets HER2?

Trastuzumab.

Which side effect is linked to tamoxifen?

Endometrial hyperplasia and cancer.